Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.04.07
- Author:
Benlin HUANG
1
,
2
,
3
;
Yong DUAN
1
,
2
,
3
Author Information
1. Department of Clinical Laboratory, the First Affiliated Hospital of Kunming Medical University
2. Yunnan Institute of Experimental Diagnosis
3. Yunnan Key Laboratory of Laboratory Medicine, Kunming 650032, China.
- Publication Type:Journal Article
- Keywords:
CTLA-4;
Immune checkpoint inhibitors;
PD-1;
PD-L1;
Small cell lung cancer
- MeSH:
Humans;
Lung Neoplasms;
diagnosis;
drug therapy;
immunology;
Molecular Targeted Therapy;
methods;
Prognosis;
Small Cell Lung Carcinoma;
diagnosis;
drug therapy;
immunology
- From:
Chinese Journal of Lung Cancer
2019;22(4):239-244
- CountryChina
- Language:Chinese
-
Abstract:
With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment strategy. The appearance of immune checkpoint inhibitors brings new hope for SCLC. Several clinical trials have demonstrated the persistent efficacy and clinical activity of the programmed death receptor/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the treatment of SCLC. However, its efficacy and safety are not very accurate, and the markers that can effectively predict the efficacy of immunotherapy have not been concluded. In this paper, for further changing the treatment strategy of SCLC clinical practice and providing theoretical basis of research, we reviewed the progress of immune checkpoint inhibitors, related markers in the treatment of SCLC by exploring the value, problems and challenges of immunotherapy in SCLC.
.
